Email
Print
The Gastroesophageal Junction Carcinoma Treatments Market is estimated to grow at a CAGR of 10.5% over the forecast period of 2023-2028 and garner a market size equivalent to $2.6 billion in 2028. The Gastroesophageal form of cancer develops in between the food pipe
and the stomach. Gastroesophageal Junction Carcinoma often belongs to one of the three sub-categories, including type 1, type 2 and type 3. All
of the types differ in terms of tumor progression, size and location. Some of
the critical symptoms of esophageal adenocarcinoma are chest pain, fatigue,
heartburn, indigestion and dysphagia. Research within the field
of oncology aids the overall treatment aspect of the market. Lastly, the
growing consumption of alcohol and tobacco, supplemented by the heightened incidence
of GERD and obesity, would allow the market to grow.
Gastroesophageal Junction Carcinoma Treatment Market Drivers
Growing Obesity Cases across the Western Region:
High obesity risk is directly correlated with a higher incidence of GEJ due to factors such as altered intestinal microbiome, metabolic syndrome and low-grade inflammation. Obesity prevalence across the world tends to run high, especially in western countries due to a sedentary lifestyle and other reasons. As per CDC Update, nearly 41.3% of the entire U.S. population was termed obese during 2017-2020. Further, as per Health Express, 29% of men and 27% of women in the U.K. are obese.
For More Queries About "Gastroesophageal Junction Carcinoma Treatment Market" @ https://www.industryarc.com/support.php?id=17548
Substantial Geriatric Population Aids in the Development of GERD Correlating to an Increase in Gastroesophageal Junction Carcinoma:
The incidence of GERD runs high in the senior population due to various physiological factors. Critically, GERD incidence directly aids the development of the GEJ, boosting the overall treatment market. Lastly, a fast-growing aging population across the world assists in the increment of esophageal cancer cases. As per OECD, nearly 10% of the world population was senior/old in 2020.
Clinical Trial and Product Approval
In October 2022, Leap Therapeutics Inc, a company focusing on
targeted and immune-oncology therapeutics, announced enrollment for the
randomized controlled Part C of the ongoing DisTinGuish study to evaluate
DKN-01. This helps in the treatment of gastric and gastroesophageal
junction cancer. In 2021, the U.S. FDA approved an antibody-drug conjugate fam-trastuzumab
deruxtecan. This form of treatment would be used to treat patients
suffering from HER2-positive geriatric cancer while also assisting the GEJ
adenocarcinoma post-chemotherapy.
The Major Players in the Market
The Major Players in the Gastroesophageal Junction Carcinoma Treatment market include Astellas Pharma, BAYER AG, BeiGene Ltd, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Merck and Co, Pfizer Inc and Ono Pharmaceuticals.